{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:38:42Z","timestamp":1773920322428,"version":"3.50.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In a real-world cohort of rheumatoid arthritis (RA) patients who were unable to discontinue glucocorticoids (GCs) despite prior therapies, we aimed to evaluate the GC-sparing effect of baricitinib (BARI) and to identify clinical factors associated with GC reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This single-center retrospective observational study included RA patients who initiated BARI while receiving systemic GCs between 2018 and 2024. Disease activity and daily GC dose were assessed at baseline and at weeks 4, 12, and 24. The primary outcome was the percent reduction in daily GC dose at week 24. Linear and logistic regression analyses were performed to identify factors associated with GC reduction and discontinuation, with two-variable multivariable models constructed to avoid overfitting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 177 patients who initiated BARI, 39 (22%) were receiving GCs at treatment initiation and were included in the analysis. After prior exposure to biologic or targeted synthetic DMARDs in 31 patients (79%), 34 (87%) had moderate or higher disease activity by the Clinical Disease Activity Index at baseline, and 27 (69%) had comorbid interstitial lung disease. The median daily GC dose decreased from 3.0 mg\/day at baseline to 1.0 mg\/day at week 24 (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), with a significant reduction observed as early as week 4. The median GC reduction rate at week 24 was 66%, with 18 of 39 patients (46%) achieving a \u2265 50% reduction and 10 patients (26%) discontinuing GCs entirely. Disease activity improved significantly, with 62% of patients achieving remission or low disease activity by week 24. In linear regression analysis, refractoriness to \u2265 2 prior biologic or targeted synthetic DMARDs was independently associated with a smaller degree of GC reduction. No unexpected safety signals were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort of GC-dependent RA patients with persistent disease activity and frequent ILD comorbidity despite prior therapies, BARI enabled clinically meaningful GC reduction and improved disease activity within 24 weeks. Resistance to multiple prior b\/tsDMARDs emerged as a key barrier to GC tapering, highlighting the importance of introducing JAK inhibitors before progression to a difficult-to-treat state.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1797242","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:51:25Z","timestamp":1773903085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucocorticoid reduction with baricitinib in rheumatoid arthritis refractory to prior therapies: a 24-week real-world analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Takashi","family":"Yamane","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Kakogawa Central City Hospital","place":["Kakogawa, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kakogawa Central City Hospital","place":["Kakogawa, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kakogawa Central City Hospital","place":["Kakogawa, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kakogawa Central City Hospital","place":["Kakogawa, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hashiramoto","sequence":"additional","affiliation":[{"name":"Department of Biophysics, Kobe University Graduate School of Health Sciences","place":["Kobe, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"870","DOI":"10.7326\/M20-1594","article-title":"Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis : a cohort study.","volume":"173","author":"George","year":"2020","journal-title":"Ann Intern Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00198-024-07023-6","article-title":"Average daily glucocorticoid dose, number of prescription days, and cumulative dose in the initial 90 days of glucocorticoid therapy are associated with subsequent hip and clinical vertebral fracture risk: a retrospective cohort study using a nationwide health insurance claims database in Japan.","volume":"35","author":"Iki","year":"2024","journal-title":"Osteoporos Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1210\/jc.2019-00153","article-title":"Dose dependency of iatrogenic glucocorticoid excess and adrenal insufficiency and mortality: a cohort study in England.","volume":"104","author":"Mebrahtu","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/art.42860","article-title":"2023 American college of rheumatology (ACR)\/American college of chest physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases.","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.55563\/clinexprheumatol\/nyu9er","article-title":"Challenges and insights in managing difficult-to-treat rheumatoid arthritis: real-world clinical perspectives.","volume":"42","author":"Alp","year":"2024","journal-title":"Clin Exp Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1007\/s10067-025-07683-7","article-title":"ANAs and triple positivity effect on disease activity and sustained remission in rheumatoid arthritis: a retrospective real-world machine learning approach.","volume":"44","author":"Maldonado-Ca\u00f1\u00f3n","year":"2025","journal-title":"Clin Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1136\/ard-2022-222405","article-title":"Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.","volume":"81","author":"Balanescu","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis.","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13075-025-03645-1","article-title":"Evolution from early to difficult-to-treat rheumatoid arthritis: incidence and risk factors in the ERA uclouvain Brussels cohort.","volume":"27","author":"Natalucci","year":"2025","journal-title":"Arthritis Res Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/rheumatology\/keac563","article-title":"Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: a multicentre cohort study.","volume":"62","author":"Giollo","year":"2023","journal-title":"Rheumatology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system.","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2531204","DOI":"10.1001\/jamanetworkopen.2025.31204","article-title":"Comparative safety of JAK inhibitors vs TNF antagonists in immune-mediated inflammatory diseases: a systematic review and meta-analysis.","volume":"8","author":"Solitano","year":"2025","journal-title":"JAMA Netw Open."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1376476","DOI":"10.3389\/fimmu.2024.1376476","article-title":"The steroid-sparing effect of JAK inhibitors across multiple patient populations.","volume":"15","author":"Conigliaro","year":"2024","journal-title":"Front Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"105671","DOI":"10.1016\/j.jbspin.2023.105671","article-title":"Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: results from the international TOCERRA and PANABA observational collaborative studies.","volume":"91","author":"Lauper","year":"2024","journal-title":"Joint Bone Spine."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/rheumatology\/keae455","article-title":"Glucocorticoid sparing effect of Janus kinase inhibitors compared to biologic disease modifying anti-rheumatic drugs in rheumatoid arthritis, a single-centre retrospective analysis.","volume":"64","author":"Adami","year":"2025","journal-title":"Rheumatology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e002792","DOI":"10.1136\/rmdopen-2022-002792","article-title":"Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs).","volume":"9","author":"Adami","year":"2023","journal-title":"RMD Open."},{"key":"B20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/14397595.2017.1369926","article-title":"Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.","volume":"28","author":"Shimizu","year":"2018","journal-title":"Mod Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40744-025-00747-9","article-title":"Effective second-line b\/tsDMARDs for patients with rheumatoid arthritis unresponsive to first-line b\/tsDMARDs from the FIRST registry.","volume":"12","author":"Kanda","year":"2025","journal-title":"Rheumatol Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"868","DOI":"10.55563\/clinexprheumatol\/pudtpo","article-title":"Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study.","volume":"39","author":"Guidelli","year":"2021","journal-title":"Clin Exp Rheumatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40744-025-00781-7","article-title":"Patient profile and outcomes among patients with rheumatoid arthritis treated with Baricitinib versus other therapies in Spain: the RA-BE-REAL study.","volume":"12","author":"Garc\u00eda-Vivar","year":"2025","journal-title":"Rheumatol Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e004987","DOI":"10.1136\/rmdopen-2024-004987","article-title":"Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry.","volume":"11","author":"Miyazaki","year":"2025","journal-title":"RMD Open."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e005062","DOI":"10.1136\/rmdopen-2024-005062","article-title":"Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study.","volume":"11","author":"Triboulet","year":"2025","journal-title":"RMD Open."},{"key":"B26","doi-asserted-by":"publisher","first-page":"103636","DOI":"10.1016\/j.autrev.2024.103636","article-title":"Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.","volume":"23","author":"Narv\u00e1ez","year":"2024","journal-title":"Autoimmun Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e22336","DOI":"10.1096\/fj.202101436R","article-title":"Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis.","volume":"36","author":"Wang","year":"2022","journal-title":"FASEB J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1136\/annrheumdis-2014-205318","article-title":"What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort.","volume":"73","author":"Takase","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13075-017-1243-y","article-title":"Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis.","volume":"19","author":"Wither","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1759720X211014019","DOI":"10.1177\/1759720X211014019","article-title":"Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience.","volume":"13","author":"Tesei","year":"2021","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s41927-024-00446-y","article-title":"Efficacy and safety of baricitinib in rheumatoid arthritis patients with moderate renal impairment: a multicenter propensity score matching study.","volume":"8","author":"Maeyama","year":"2024","journal-title":"BMC Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/ard-2023-224670","article-title":"Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the \u2018JAK-pot\u2019 study).","volume":"83","author":"Aymon","year":"2024","journal-title":"Ann Rheum Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis.","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","article-title":"Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.","volume":"77","author":"Roodenrijs","year":"2018","journal-title":"Ann Rheum Dis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1797242\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:51:26Z","timestamp":1773903086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1797242\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":35,"alternative-id":["10.3389\/fmed.2026.1797242"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1797242","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"article-number":"1797242"}}